Related Experiment Video

Updated: May 11, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Coexistence of PML-RARα and BCR-ABL in acute promyelocytic leukemia

Erin M Pettijohn1, Leonidas C Platanias, Jessica K Altman

  • 1Robert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Medical School , Chicago, IL , USA.

Leukemia & Lymphoma
|May 25, 2013
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Experiment Videos

Last Updated: May 11, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

Articles linked to this work by shared authors, journal, and citation graph.

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Haematologica·2026

Potent Anti-Glioblastoma Effects of Next-Generation MNK Inhibitors.

Cancers·2026

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

Future oncology (London, England)·2026

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.

Blood·2026

Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Blood·2026

Emerging drug profile: bexobrutideg.

Leukemia & lymphoma·2026

Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.

Leukemia & lymphoma·2026

Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies.

Leukemia & lymphoma·2026

Evaluating YouTube videos for Hodgkin lymphoma patient education.

Leukemia & lymphoma·2026

Venetoclax consolidation deepens response and enables measurable residual disease-guided finite therapy in BTK inhibitor-treated chronic lymphocytic leukemia.

Leukemia & lymphoma·2026

Clinical outcomes of adults with PAX5-mutated or rearranged B-cell acute lymphoblastic leukemia.

Leukemia & lymphoma·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us